The Impact of Dual Antiplatelet Therapy Strategies After Coronary Intervention on Clinical Prognosis of Patients
-
摘要:
目的 探讨冠脉介入术后不同双联抗血小板治疗(dual antiplatelet therapy,DAPT)策略对患者临床预后的影响及与终点事件风险的关联。 方法 本随机对照研究连续纳入2023年1月至2024年12月于淮南市东方医院集团总院治疗的冠脉介入术后患者,经纳入与排除标准筛选初步纳入148例,研究期间脱落6例,最终142例患者完成12个月随访并纳入统计分析,随机分为标准组与降阶组。标准组接受12个月标准DAPT方案,降阶组前3个月同标准组,后转换为温和抗血小板治疗。比较两组非致死性心肌梗死、脑卒中、出血事件等终点事件发生率、出血分型,并进行单、多因素分析。 结果 142例患者进入最终统计分析,其中标准组71例,年龄(63.22 ± 8.14)岁,男41例(57.8%),降阶组71例,年龄(62.73 ± 7.90)岁,男43例(60.6%),两组基线资料差异无统计学意义(P > 0.05)。降阶组出血事件发生率(4.2%比18.3%,P = 0.008)、终点事件总发生率(14.1%比29.6%,P = 0.025)低于标准组(P < 0.05)。两组出血分型整体比较差异有统计学意义(P = 0.008),且降阶组2型及以上出血占比低于标准组(P = 0.042)。发生组标准DAPT方案占比(67.8%比45.1%,P = 0.025)、术前SYNTAX积分[(39.40 ± 5.12)分比(28.94 ± 4.23)分]、术前N末端B型利钠肽原[185.60(62.37,420.53)pg/mL比119.34(45.52,337.15)pg/mL]均高于发生组(P < 0.05)。DAPT方案、术前SYNTAX积分、术前N末端B型利钠肽原均是终点事件发生的影响因素(P < 0.05)。 结论 冠脉介入术后患者采用DAPT降阶策略可降低出血及终点事件发生率,安全性与有效性更优,可为临床个体化抗血小板治疗与预后评估提供重要依据。 Abstract:Objective To explore the influence of different dual antiplatelet therapy (DAPT) strategies after coronary intervention on the clinical prognosis of patients and their association with the risk of endpoint events, and to provide evidence-based support for optimizing postoperative antiplatelet regimens. Methods This randomized controlled study consecutively included patients who underwent coronary intervention in Huainan City Dongfang Hospital Group Headquarters from January 2023 to December 2024. After screening based on inclusion and exclusion criteria, 148 patients were initially included, with 6 patients dropping out during the study period. Ultimately, 142 patients completed 12-month follow-up and were included in the statistical analysis, and were randomly divided into the standard group and the de-escalation group. The standard group received a 12-month standard DAPT regimen, while the de-escalation group followed the same regimen for the first 3 months and then switched to a milder antiplatelet therapy. The incidence of non-fatal myocardial infarction, stroke, bleeding events, and bleeding types were compared between the two groups, and univariate and multivariate analyses were conducted. Results A total of 142 patients were included in the final statistical analysis. Among them, 71 were in the standard group, with an average age of (63.22 ± 8.14) years, and 41 were male (57.8%). Another 71 were in the descending-dose group, with an average age of (62.73 ± 7.90) years, and 43 were male (60.6%). There were no statistically significant differences in baseline data between the two groups (P > 0.05). The incidence of bleeding events (4.2% vs. 18.3%, P = 0.008) and the total incidence of endpoint events (14.1% vs. 29.6%, P = 0.025) were lower in the de-escalation group than in the standard group (P < 0.05). There was a statistically significant difference in the overall comparison of the two groups of bleeding types (P = 0.008), and the proportion of type 2 and above bleeding in the descending grade group was lower than that in the standard group (P = 0.042). The proportion of patients receiving the standard DAPT regimen (67.8% vs. 45.1%, P = 0.025), preoperative SYNTAX score [(39.40 ± 5.12) points vs. (28.94 ± 4.23) points], and preoperative N-terminal pro-B-type natriuretic peptide [185.60 (62.37, 420.53) pg/mL vs. 119.34 (45.52, 337.15) pg/mL] were higher in the occurrence group than in the non-occurrence group (P < 0.05). DAPT regimen, preoperative SYNTAX score, and preoperative N-terminal pro-B-type natriuretic peptide were independent influencing factors for the occurrence of endpoint events (P < 0.05). Conclusion A de-escalation strategy of DAPT in patients after coronary intervention can reduce the incidence of bleeding and adverse events, offering superior safety and efficacy, and providing important evidence for individualized antiplatelet therapy and prognosis assessment in clinical practice. -
表 1 出血分型判定细则
Table 1. Criteria for determining blood loss types
出血类型 判定标准 0型 无出血 1型 轻微出血(如皮肤瘀斑、鼻出血等),
无需医疗干预或导致治疗调整2型 明显出血,需要医疗干预(如药物治疗)或导致
住院/提升护理级别,但未达到3型严重程度3型 临床显著出血:包括3a型(血红蛋白下降 > 30 g/L
或需输血)、3b型(导致血红蛋白下降≥50 g/L、
心脏压塞、需外科手术或静脉血管活性药物)、
3c型(颅内出血或损害视力的眼内出血)4型 围术期48 h内颅内出血、因出血再次手术、
大量输血(48小时内≥5 U)或
大量胸腔引流(24 h内≥2 L)5型 致死性出血 表 2 两组基本资料比较[($ \bar x \pm s $)/n(%)/ M(P25,P75)]
Table 2. Comparison of the basic data of the two groups[($ \bar x \pm s $)/n(%)/ M(P25,P75)]
资料 标准组(n = 71) 降阶组(n = 71) χ2/t/Z P 男 41(57.8) 43(60.6) 0.117 0.733 年龄(岁) 63.22 ± 8.14 62.73 ± 7.90 0.361 0.718 糖尿病 22(31.0) 24(33.8) 0.129 0.720 高血压 52(73.2) 49(69.0) 0.309 0.579 高脂血症 37(52.1) 39(54.9) 0.113 0.736 冠心病家族史 12(16.9) 14(19.7) 0.188 0.664 吸烟 27(38.0) 25(35.2) 0.121 0.728 饮酒 20(28.2) 18(25.4) 0.144 0.705 急性冠脉综合征分型 0.462 0.794 不稳定型心绞痛 24(33.8) 22(31.0) 非ST段抬高型心肌梗死 30(42.3) 34(47.9) ST段抬高型心肌梗死 17(23.9) 15(21.1) 术前SYNTAX积分(分) 30.85 ± 4.38 31.59 ± 4.10 1.039 0.300 术前肌酸激酶同工酶(ng/mL) 11.01(8.20,14.35) 11.25(8.76,13.43) 0.040 0.968 术前高敏肌钙蛋白Ⅰ(ng/mL) 0.11(0.10,0.48) 0.13(0.10,0.50) 0.091 0.928 术前N末端B型利钠肽原(pg/mL) 119.32(45.51,337.17) 123.11(50.24,326.82) 0.164 0.872 药物依从性良好 68(95.8) 69(97.2) 0.000 1.000 表 3 两组终点事件发生率比较[n(%)]
Table 3. Comparison of the incidence rates of the two groups of endpoint events[n(%)]
终点事件 标准组(n = 71) 降阶组(n = 71) χ2 P 非致死性心肌梗死 2(2.8) 2(2.8) 0.000 1.000 脑卒中 2(2.8) 0(0.0) 0.507 0.476 心源性死亡 3(4.2) 2(2.8) 0.000 1.000 出血事件 13(18.3) 3(4.2) 7.044 0.008* 靶血管血运重建 1(1.4) 3(4.2) 0.257 0.612 总发生率 21(29.6) 10(14.1) 4.993 0.025* *P < 0.05。 表 4 两组出血分型的比较[n(%)]
Table 4. Comparison of the two groups of bleeding classifications[n(%)]
分型 标准组(n = 71) 降阶组(n = 71) Z P 0型 58(81.7) 68(95.8) 2.639 0.008* 1型 3(4.2) 0(0.0) 2型 4(5.6) 2(2.8) 3型 5(7.0) 1(1.4) 4型 1(1.4) 0(0.0) 2型及以上 10(14.1) 3(4.2) 4.149 0.042* *P < 0.05。 表 5 终点事件发生的单因素分析[($ \bar x \pm s $)/n(%)/ M(P25,P75)]
Table 5. Univariate analysis of the occurrence of the terminal event[($ \bar x \pm s $)/n(%)/ M(P25,P75)]
资料 未发生组(n = 111) 发生组(n = 31) χ2/t/Z P 年龄(岁) 62.51 ± 8.23 65.80 ± 9.11 1.922 0.057 糖尿病 32(28.8) 14(45.2) 2.952 0.086 高血压 78(70.3) 23(74.2) 0.182 0.670 高脂血症 58(52.3) 18(58.1) 0.329 0.566 冠心病家族史 18(16.2) 8(25.8) 1.490 0.222 吸烟 40(36.0) 12(38.7) 0.075 0.785 饮酒 30(27.0) 8(25.8) 0.018 0.892 急性冠脉综合征分型 0.661 0.719 不稳定型心绞痛 35(31.5) 11(35.5) 非ST段抬高型心肌梗死 52(46.8) 12(38.7) ST段抬高型心肌梗死 24(21.6) 8(25.8) DAPT方案 4.993 0.025* 标准 50(45.1) 21(67.8) 降阶 61(55.0) 10(32.3) 术前SYNTAX积分(分) 28.94 ± 4.23 39.40 ± 5.12 11.608 < 0.001* 术前肌酸激酶同工酶(ng/mL) 11.03(8.24,14.3) 12.21(8.53,14.82) 0.315 0.521 术前高敏肌钙蛋白Ⅰ(ng/mL) 0.17(0.12,0.47) 0.20(0.13,0.52) 0.493 0.337 术前N末端B型利钠肽原(pg/mL) 119.34(45.52,337.15) 185.60(62.37,420.53) 2.458 0.014* DAPT:双联抗血小板治疗;*P < 0.05 表 6 终点事件发生的多因素分析
Table 6. Multifactorial analysis of the occurrence of the terminal event
影响因素 β SE Wald χ2 OR 95%CI P VIF DAPT方案 1.108 0.226 24.017 3.027 1.944~4.714 < 0.001* 1.653 术前SYNTAX积分 0.999 0.312 10.248 2.715 1.473~5.004 0.001* 3.224 术前N末端B型利钠肽原 1.048 0.412 6.475 2.853 1.272~6.397 0.011* 1.271 DAPT:双联抗血小板治疗;*P < 0.05 -
[1] Ye X, Wang S, Liu X A, et al. Effects of PCSK9 inhibitors on coronary microcirculation, inflammation and cardiac function in patients with CHD after PCI: A protocol for systematic review and meta-analysis[J]. BMJ Open, 2023, 13(9): e074067. doi: 10.1136/bmjopen-2023-074067 [2] Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial[J]. JAMA Cardiol, 2022, 7(4): 407-417. doi: 10.1001/jamacardio.2021.5244 [3] Woelders E C I, Luijkx J J P, Rodwell L, et al. Outcomes with P2Y12 inhibitor monotherapy after PCI according to bleeding risk: A Bayesian meta-analysis[J]. Cardiovasc Revasc Med, 2023, 55: 44-51. doi: 10.1016/j.carrev.2023.05.001 [4] Valgimigli M, Hong S J, Gragnano F, et al. De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: A systematic review and individual patient-level meta-analysis of randomised trials[J]. Lancet, 2024, 404(10456): 937-948. doi: 10.1016/S0140-6736(24)01616-7 [5] Kuno T, Watanabe A, Shoji S, et al. Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes: A systematic review and network meta-analysis[J]. Circ Cardiovasc Interv, 2023, 16(9): e013242. [6] Kang J, Rizas K D, Park K W, et al. Dual antiplatelet therapy de-escalation in acute coronary syndrome: An individual patient meta-analysis[J]. Eur Heart J, 2023, 44(15): 1360-1370. [7] Buske M, Feistritzer H J, Jobs A, et al. Management des akuten Koronarsyndroms: Management of acute coronary syndrome: ESC guidelines 2023[J]. Herz, 2024, 49(1): 5-14. doi: 10.1007/s00059-023-05222-1 [8] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版)[J]. 实用肝脏病杂志, 2013, 15(3): 210-216. doi: 10.3969/j.issn.1672-5069.2019.02.004 [9] 徐钢. 肾脏病诊疗指南[M]. 第3版. 北京: 科学出版社, 2013. [10] 瞿建宇, 陈思, 王志坚, 等. 冠状动脉旁路移植术后双联抗血小板治疗改善中远期临床预后: DACAB-FE研究解读[J]. 中国胸心血管外科临床杂志, 2024, 31(8): 1096-1100. doi: 10.7507/1007-4848.202406070 [11] 李世英, 柳景华. 欧美出血学术研究会(BARC)关于出血的统一定义[J]. 中国介入心脏病学杂志, 2012, 20(4): 231-234. doi: 10.3969/j.issn.1004-8812.2012.04.015 [12] Tan J W, Chew D P, Ali S K Abdul Kader M, et al. 2020 Asian Pacific society of cardiology consensus recommendations on the use of P2Y12 receptor antagonists in the Asia-Pacific region[J]. Eur Cardiol, 2021, 16: e02. doi: 10.15420/ecr.2020.40 [13] 李雅超, 雷梦杰, 杨彦立, 等. 双联抗血小板药物降阶方案对经皮冠状动脉介入治疗的ACS患者预后的影响[J]. 心脑血管病防治, 2025, 25(1): 25-28. doi: 10.3969/j.issn.1009-816x.2025.01.007 [14] 王蓉, 胡东南, 王进, 等. 双联抗血小板降阶治疗经皮冠状动脉介入治疗后血栓高危患者的有效性及安全性研究[J]. 实用心脑肺血管病杂志, 2022, 30(2): 33-38. doi: 10.12114/j.issn.1008-5971.2022.00.041 [15] Ge Z, Kan J, Gao X, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): A randomised, placebo-controlled, double-blind clinical trial[J]. Lancet, 2024, 403(10439): 1866-1878. doi: 10.1016/S0140-6736(24)00473-2 [16] Li Y, Li J, Wang B, et al. Extended clopidogrel monotherapy vs DAPT in patients with acute coronary syndromes at high ischemic and bleeding risk: The OPT-BIRISK randomized clinical trial[J]. JAMA Cardiol, 2024, 9(6): 523-531. doi: 10.1001/jamacardio.2024.0534 [17] Munafò A R, Montalto C, Franzino M, et al. External validity of the PRECISE-DAPT score in patients undergoing PCI: A systematic review and meta-analysis[J]. Eur Heart J Cardiovasc Pharmacother, 2023, 9(8): 709-721. doi: 10.1093/ehjcvp/pvad063 [18] 莫叶, 邢波. 冠状动脉CTA-SYNTAX评分与冠状动脉造影SYNTAX评分的相关性[J]. 中南大学学报(医学版), 2021, 46(8): 884-888. doi: 10.11817/j.issn.1672-7347.2021.200837 [19] Lu P J, Gong X W, Liu Y, et al. Optimization of GRACE risk stratification by N-terminal pro-B-type natriuretic peptide combined with D-dimer in patients with non-ST-elevation myocardial infarction[J]. Am J Cardiol, 2021, 140: 13-19. doi: 10.1016/j.amjcard.2020.10.050 [20] Pei J, Cai L, Wang F, et al. LPA2 contributes to vascular endothelium homeostasis and cardiac remodeling after myocardial infarction[J]. Circ Res, 2022, 131(5): 388-403. doi: 10.1161/CIRCRESAHA.122.321036 -
下载: